Roche Reports P-III (IMscin001) Study Results of Subcutaneous Formulation of Tecentriq for the Treatment of Non-Small Cell Lung Cancer
- The P-III (IMscin001) study evaluating the PK, safety & efficacy of Tecentriq as SC formulation vs IV Tecentriq in 371 patients with prior treated LA or metastatic NSCLC.
- The trial met its co-primary EPs & showed non-inferior levels of Tecentriq in the blood over IV infusion in cancer immunotherapy-naïve patients, Tecentriq (SC) decreased the treatment period from 30 to 60min. to 3 to 8min. per inj. The safety profile of the SC formulation was consistent with that of IV Tecentriq
- The results will be shared at an upcoming medical meeting & submit to health authorities globally for regulatory approval incl. the US FDA & EMA. Tecentriq is a mAb targeting PD-L1 acts by blocking its interactions with PD-1 & B7.1 receptor
Ref: Roche | Image: Roche
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.